Reaction

Rectal Cancer reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,040 reports · 49 co-occurring drugs

As of the last recalculation, Rectal Cancer appears in 3,040 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 59.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Regorafenib	98	59.7	60.2
Panitumumab	46	20.4	20.5
Irinotecan Hydrochloride	33	17.8	17.8
Trifluridine And Tipiracil	14	9.0	9.0
Leucovorin Calcium	23	8.3	8.3
Oxaliplatin	85	8.0	8.0
Fluorouracil Cream, 0.5%	86	7.9	7.9
Fluorouracil	86	7.8	7.8
Diphenoxylate Hydrochloride And Atropine Sulfate	15	7.5	7.5
Methadone	44	7.1	7.1
Capecitabine	83	6.4	6.4
Bicalutamide	13	5.9	5.9
Abacavir Sulfate	8	5.6	5.6
Infliximab	164	5.4	5.4
Pitavastatin Calcium	8	5.4	5.4
Bevacizumab	89	5.0	5.0
Amlodipine Besylate And Valsartan	8	5.0	5.0
Ranitidine Hydrochloride	38	4.8	4.8
Entecavir	8	4.7	4.7
Fulvestrant	22	4.6	4.6
Prochlorperazine Maleate	6	4.5	4.5
Cetuximab	20	4.4	4.4
Ribociclib	20	4.4	4.4
Mesalamine	33	4.1	4.1
Pioglitazone	25	4.0	4.0
Imatinib	10	3.9	3.9
Risankizumab-Rzaa	40	3.4	3.4
Prasugrel Hydrochloride	5	3.4	3.4
Dabigatran Etexilate	37	3.3	3.3
Dabigatran Etexilate Mesylate	34	3.2	3.2
Tofacitinib Citrate	6	3.1	3.1
Fentanyl Citrate	8	3.1	3.1
Ustekinumab	45	3.0	3.0
Gefitinib	4	3.0	3.0
Apalutamide	5	2.9	2.9
Upadacitinib	32	2.7	2.7
Ranitidine	76	2.7	2.7
Inclisiran	3	2.6	2.6
Golimumab	30	2.4	2.4
Diroximel Fumarate	4	2.3	2.3
Dasatinib	12	2.2	2.2
Aflibercept	10	2.2	2.2
Polatuzumab Vedotin	3	2.1	2.1
Encorafenib	3	2.1	2.1
Ravulizumab	4	2.0	2.0
Leuprolide Acetate	22	1.9	1.9
Ranibizumab	7	1.8	1.8
Enzalutamide	14	1.6	1.6
Guselkumab	6	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.